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A 47-year-old woman with superior vena cava syndrome (SVCS) presented a metastatic small-cell lung cancer 
(SCLC). An initial computed tomography revealed a large 
tumor of the right lung, compressing the superior vena cava 
(Fig. 1A). A vena cava stent was inserted at the time of diag-
nosis and the patient was sent for chemotherapy. After the 
patient was administered four courses of chemotherapy by 
cisplatin and etoposide, the computed tomography revealed 
a partial tumor response (Fig. 1B) and migration of the stent 
into the left pulmonary artery (Fig. 2). Because of the poor 
oncological prognosis and the asymptomatic character of 
the migration, surgery was not indicated. Anticoagulation 
treatment was challenged because of the risk of hemor-
rhage. The patient died 3 months later because of a hepatic 
encephalopathy.
Migration of an endoprosthesis can lead to potentially 
serious complications and is estimated at 3%1,2 Some authors 
suggest that the vena cava stent should be avoided in patients 
with SCLC because of the chemo- and radiosensitive nature of 
this histologic type of cancer, which increases the risk of stent 
migration because of rapid tumor shrinkage under treatment.1 
In some cases of acute SVCS spectacular clinical results could 
be observed during the 24 to 48 hours after insertion of the 
stent, whereas the efficacy of chemotherapy or radiotherapy 
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FIGURE 1. A, Initial chest CT scan showing vena cava stenosis caused by a mediastinal mass (arrow). B, Chest CT scan showing 
a normal diameter of vena cava after four courses of chemotherapy (arrow). CT, computed tomography.
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was not observed until 3 to 4 weeks after.2,3 The insertion of a 
vena cava stent must be avoided in SVCS caused by SCLC.2
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FIGURE 2. A, CT scan: coronal reconstruction with projection of the prosthesis at the dome of the left pulmonary artery 
(arrow). B, CT scan: horizontal section with a thrombosed prosthesis obstructing the the left lower lobe artery (arrow). CT, 
computed tomography.
Erratum
Overexpression of EPH Receptor B2 in Malignant 
Mesothelioma Correlates with Oncogenic 
Behavior: Erratum
We would like to point out a methodologic error regarding peptide sc-1763P from Santa Cruz which we used for part of our EphB2 functional assays. 
SC-1763P is, in reality, not an EphB2 blocking peptide, and in fact is sold as a control to block the anti-EphB2 antibody sc-1763P. Hence, based on the 
information available on the sc-1763P peptide the effects we observed in the experiments shown in Fig. 5 are nonspecific effects and should not be attributed 
to inhibiting EphB2. our shRNA data in the manuscript, however, will stand as proof of principle for the demonstration of the functional events associated 
with EphB2 in mesothelioma. our gratitude to Dr. Elaine Pasquale, Professor at the Sanford-Burnham Medical Research Institute in La Jolla and an inter-
nationally renowned ephrin expert, for pointing out this error. Harvey I. Pass, MD Chandra Goparaju, PhD NYU Langone Medical Center New York, NY
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